Day: February 25, 2025

– ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 – $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren’s Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full...

LIMA, Peru, February 25, 2025 — Camposol Holding PLC (Camposol or the Company), a multinational company dedicated to providing fresh and healthy food globally, today announced its preliminary financial results for year ended December 31, 2024. These results have been prepared in accordance with International Financial Reporting Standards (IFRS) and are subject to change based on the issuance of the Company’s audited financial statements. Camposol Achieves Record EBITDA of USD 184.1 million in 2024, and a Net Debt to EBITDA ratio of 2.41x, Highlighting Market Leadership in Key Exports and Financial Discipline. 1) Full year 2024 Financial Overview:Volume Sold: Totaled 112,564 MT, a 6% decrease compared to 2023. Sales: USD 550 million, marking an 18% growth compared to USD 464 million in 2023. EBITDA: USD 184.1 million, a 68% increase...

THE WOODLANDS, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the fourth quarter and year ended December 31, 2024. “In the face of a mixed macroeconomic backdrop, our strong finish in the fourth quarter enabled us to meet, and in many cases exceed, our strategic goals for 2024,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes. “Our strong execution in the fourth quarter resulted in full year closings of 6,131 homes, including the bulk sale of 103 leased, single-family homes. We successfully ended the year with a record high 151 active communities, an impressive increase of 29.1%. We made significant progress improving profitability. Our full year gross margin was 24.2% and adjusted gross margin was 26.3%. These results represented increases of 120...

― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quarter and full year of 2024 as well as a business update. “We are entering 2025 with strong momentum behind our lead program, pociredir, for the treatment of sickle cell disease,”...

2024 HighlightsNet revenue of $5.9 billion in 2024, an increase of 15.8% over 2023; Adjusted EBITDA1 of $980.3 million, up 18.0% over 2023, and adjusted EBITDA margin1 of 16.7%, a 30-basis point increase over 2023; Strong organic growth of 7.4% for the full year driven by 8.6% organic growth in the US, 6% in Canada, and 5.8% in Global; Operating cash flows increased to $603.1 million, up 16.0% over 2023; Adjusted diluted EPS1 of $4.42, an increase of 20.4% over 2023; Backlog of $7.8 billion, up 24.1% since December 31, 2023, and; Ranked #8 of the most sustainable corporations in the world by Corporate Knights, first among peers.EDMONTON, Alberta and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) — TSX, NYSE:STN Stantec, a global leader in sustainable design and engineering, released its results today for the fourth quarter and year...

– Quarterly Revenue of $107.0 million – – Adjusted Gross Profit Percentage1 of 37.6% – – Quarterly Net Income of $7.8 million – – Adjusted EBITDA1 of $26.4 million – – Ending Backlog and Awarded Orders of $634.7 million – – Provides First Quarter and Full Year 2025 Outlook – PORTLAND, Tenn., Feb. 25, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components, including battery energy storage solutions (“BESS”), and Original Equipment Manufacturer (“OEM”) components for the global energy transition market, today announced results for its fourth quarter ended December 31, 2024. “2024 proved to be an unpredictable year for the US utility scale solar industry. A rapidly shifting political landscape, supply chain...

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Ended Fourth Quarter 2024 with $850.7 Million in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through...

SINGAPORE, Feb. 25, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance computing, today released its unaudited financial results for the fourth quarter ended December 31, 2024. Q4 2024 Financial HighlightsAll amounts compared to Q4’23 unless otherwise notedTotal revenue was US$69.0 million vs. US$114.8 million. Cost of revenue was US$63.9 million vs. US$87.8 million. Gross profit was US$5.1 million vs. US$27.0 million. Net loss was US$531.9 million vs. US$5.0 million. Adjusted EBITDA1 was negative US$3.8 million, vs. positive US$33.32 million. Cash and cash equivalents were US$476.3 million as of December 31, 2024. Crypto balance: US$77.5 million as of December 31, 2024.Management Commentary “Last year, we strategically...